Advertisement

Advertisement

CLYM Stock Latest News

Climb Bio price target raised to $24 from $20 at H.C. Wainwright

The FlyClimb Bio price target raised to $24 from $20 at H.C. Wainwright

CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy Outlook

PremiumRatings

CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy Outlook

8d ago

Climb Bio Advances Phase 2 Renal Disease Trial

PremiumCompany Announcements

Climb Bio Advances Phase 2 Renal Disease Trial

13d ago

Climb Bio price target raised to $25 from $17 at Truist

PremiumThe Fly

Climb Bio price target raised to $25 from $17 at Truist

19d ago

Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data

PremiumCompany Announcements

Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data

20d ago

Climb Bio reports Q2 EPS (18c), consensus (21c)

PremiumThe FlyClimb Bio reports Q2 EPS (18c), consensus (21c)

21d ago

Climb Bio initiated with an Outperform at RBC Capital

The Fly

Climb Bio initiated with an Outperform at RBC Capital

24d ago

Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst

Company Announcements

Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst

27d ago

PremiumRatings

Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price Target

1M ago

Climb Bio Appoints Breanna O’Reilly to Board

PremiumCompany Announcements

Climb Bio Appoints Breanna O’Reilly to Board

2M ago

Climb Bio Buy Rating Reiterated as Advancing Pipeline Supports Maintained $20 Price Target

PremiumRatings

Climb Bio Buy Rating Reiterated as Advancing Pipeline Supports Maintained $20 Price Target

2M ago

Climb Bio Establishes New At-the-Market Equity Program

PremiumCompany Announcements

Climb Bio Establishes New At-the-Market Equity Program

3M ago

Climb Bio price target raised to $20 from $19 at BTIG

PremiumThe FlyClimb Bio price target raised to $20 from $19 at BTIG

3M ago

Climb Bio announces initial data from budoprutug study at EHA

The Fly

Climb Bio announces initial data from budoprutug study at EHA

3M ago

Climb Bio Reports Encouraging Early Budoprutug ITP Data

Company Announcements

Climb Bio Reports Encouraging Early Budoprutug ITP Data

3M ago

Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors

PremiumCompany Announcements

Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors

3M ago

Climb Bio initiated with a Buy at Guggenheim

PremiumThe Fly

Climb Bio initiated with a Buy at Guggenheim

3M ago

Julian Harrison Reiterates Buy on CLYM116, Maintains $19 Price Target on Best-in-Class IgAN Potential

PremiumRatings

Julian Harrison Reiterates Buy on CLYM116, Maintains $19 Price Target on Best-in-Class IgAN Potential

3M ago

Climb Bio Reports Positive Early-Stage Data for CLYM116

PremiumCompany Announcements

Climb Bio Reports Positive Early-Stage Data for CLYM116

3M ago

Climb Bio registers to sell 11.59M shares of common stock for holders

PremiumThe FlyClimb Bio registers to sell 11.59M shares of common stock for holders

3M ago

Climb Bio price target raised to $20 from $15 at H.C. Wainwright

The Fly

Climb Bio price target raised to $20 from $15 at H.C. Wainwright

4M ago

Climb Bio price target raised to $17 from $15 at Wedbush

The Fly

Climb Bio price target raised to $17 from $15 at Wedbush

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >